MARKET

CLSD

CLSD

Clearside
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.400
+0.020
+1.45%
Pre Market: 1.410 +0.01 +0.71% 08:35 10/30 EDT
OPEN
1.380
PREV CLOSE
1.380
HIGH
1.420
LOW
1.338
VOLUME
68.34K
TURNOVER
--
52 WEEK HIGH
4.130
52 WEEK LOW
0.9620
MARKET CAP
64.88M
P/E (TTM)
-3.2154
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Clearside Biomedical (CLSD) Enters Oversold Territory
Clearside Biomedical (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Zacks · 3d ago
Clearside Biomedical presents at the Retina Society 2020 and publication of XIPERE data
Clearside Biomedical ([[CLSD]]) announced several clinical data presentations were given at the virtual 53rd Annual Scientific Meeting of The Retina Society. Also announced that data from the Company’s Phase 2 clinical
Seekingalpha · 09/23 14:20
Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE Data in Diabetic Macular Edema in Ophthalmology Retina
Presented the most robust aggregate dataset of suprachoroidal clinical injections demonstrating reliability and consistency of procedureALPHARETTA, Ga., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments
GlobeNewswire · 09/23 12:05
Clearside Biomedicals Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery
ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licensing partner, Aura
GlobeNewswire · 09/11 13:30
Clearside Biomedical Reports Its Oncology Licensing Partner Doses First Patient In Phase 2 Study In Patients With Choroidal Melanoma Using SCS Microinjector For Suprachoroidal Delivery
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced
Benzinga · 09/11 12:35
Clearside Biomedical to Present at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference
ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D.
GlobeNewswire · 09/09 20:05
Clearside Biomedicals Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal Delivery
ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licensing partner, REGENXBIO
GlobeNewswire · 09/09 13:30
Clearside Biomedical Licensing Partner REGENXBIO Doses First Patient In Phase 2 Gene Therapy Trial Using SCS Microinjector For Suprachoroidal Delivery
ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with
Benzinga · 09/09 12:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLSD. Analyze the recent business situations of Clearside through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLSD stock price target is 5.40 with a high estimate of 8.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 80
Institutional Holdings: 15.30M
% Owned: 33.01%
Shares Outstanding: 46.34M
TypeInstitutionsShares
Increased
12
846.76K
New
16
185.86K
Decreased
11
821.64K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.04%
Pharmaceuticals & Medical Research
+0.17%
Key Executives
Chairman/Independent Director
Christy Shaffer
President/Chief Executive Officer/Director
George Lasezkay
Chief Financial Officer
Charles Deignan
Independent Director
Richard Croarkin
Independent Director
Jeffrey Edwards
Independent Director
William Humphries
Independent Director
Nancy Hutson
Independent Director
Clay Thorp
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CLSD
Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Clearside Biomedical Inc stock information, including NASDAQ:CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.